سعر نيسابروفين 25مجم 30 اقراص 2022

Egyptian dexketoprofen 25 mg film-coated tablets (Sabaa / Loxxess Egypt), 30 tablets.

• Symptomatic treatment of pain of mild to moderate intensity, such as musculoskeletal pain, dysmenorrhoea and dental pain.Population: AdultsMHRA eMC

• Common (>=1/100): nausea and/or vomiting, abdominal pain, diarrhoea, dyspepsia.International label, same formulation · MHRA eMC
• Other reported reactions include headache, dizziness, somnolence, insomnia, anxiety, vertigo, palpitations, flushing, gastritis, constipation, dry mouth, flatulence, rash and fatigue; rare or very rare serious reactions include peptic ulcer bleeding/perforation, pancreatitis, anaphylaxis, Stevens-Johnson syndrome/toxic epidermal necrolysis, neutropenia, thrombocytopenia, acute renal failure and hepatocellular injury.International label, same formulation · MHRA eMC

• Hypersensitivity to dexketoprofen, any other NSAID or excipients; patients in whom aspirin/NSAIDs precipitate asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria or angioedema; known photoallergic/phototoxic reactions with ketoprofen or fibrates.International label, same formulation · MHRA eMC
• Active or history of peptic ulcer/GI bleeding or perforation (including NSAID-related), chronic dyspepsia, Crohn's disease or ulcerative colitis.International label, same formulation · MHRA eMC
• Other active bleeding, bleeding disorders, haemorrhagic diathesis or coagulation disorders.International label, same formulation · MHRA eMC

• GI bleeding, ulceration or perforation, which can be fatal, may occur at any time; risk is higher with higher doses, ulcer history and in the elderly; consider gastroprotection (misoprostol or PPI) in at-risk patients and avoid combining with other NSAIDs.International label, same formulation · MHRA eMC
• Some NSAIDs may slightly increase the risk of arterial thrombotic events (myocardial infarction, stroke); use only after careful consideration in uncontrolled hypertension, heart failure, ischaemic heart, peripheral arterial or cerebrovascular disease.International label, same formulation · MHRA eMC
• Use with caution in renal or hepatic impairment, with diuretics or hypovolaemia (risk of nephrotoxicity); ensure adequate fluid intake; discontinue if liver enzymes rise relevantly.International label, same formulation · MHRA eMC

• Other NSAIDs (including COX-2 inhibitors) and high-dose salicylates (>=3 g/day)Inadvisable: increased risk of GI ulcers and bleeding.MHRA eMC
• Anticoagulants (e.g. warfarin) and heparinsInadvisable: enhanced anticoagulant effect and bleeding risk; if unavoidable, close clinical and laboratory monitoring.MHRA eMC
• CorticosteroidsIncreased risk of GI ulceration or bleeding.MHRA eMC

• Contraindicated in the third trimester; during the first and second trimesters use only if clearly necessary, at the lowest dose for the shortest time. Early-pregnancy prostaglandin-synthesis-inhibitor use is associated with miscarriage, cardiac malformation and gastroschisis.International label, same formulation · MHRA eMC
• Contraindicated during lactation.International label, same formulation · MHRA eMC

• Dexketoprofen: Inhibits cyclo-oxygenase (COX), reducing prostaglandin synthesis.